Short answer
LEMAITRE VASCULAR INC (LMAT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $68M (up 11.3% year over year) with net income of $15M.
Q3 2026 key financials · XBRL
- Revenue
- $68M
- +11.3% YoY · −3.4% QoQ
- Net income
- $15M
- −13.5% YoY · −11.9% QoQ
- Operating margin
- 26.0%
- Gross margin
- 71.7%
- EPS (diluted)
- $0.65
- −14.5% YoY · −12.2% QoQ
Source: XBRL data from the LEMAITRE VASCULAR INC (LMAT) Q3 2026 10-Q on SEC EDGAR. USD.
LEMAITRE VASCULAR INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $68.0M, up 11% YoY from $61.0M, driven by graft sales increasing $4.5M
- Gross margin 71.7% vs 75.3% YoY, affected by 2025 ERC and $0.5M PhasTIPP excess charges
- EMEA strongest geography, revenue up 18% to $20.8M; APAC weakest, up 5% to $4.4M
- Cash $27.5M vs $28.2M at December 31, 2025; short-term securities increased to $362.2M
- Operating cash flow $53.0M vs $58.1M YoY; dividends paid $17.1M and capital expenditures $7.4M
Risk Factors
- Newly updated regulatory risk: FDA re-inspection of Artegraft facility identified additional observations in June 2026
- Most material compliance risk: FDA may impose enforcement actions if corrective actions addressing the August 2025 warning letter prove unsatisfactory
- Product liability risk: Recalls or defects could trigger significant costs, adverse publicity, and claims
- Operational risk: Ongoing Artegraft remediation requires management resources and may affect operations or sales
- Financial risk: Foreign currency exposure affected approximately 45% of sales outside the United States
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LEMAITRE VASCULAR INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.